Compound inhibiting activities of BTK and/or JAK3 kinases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9840517
APP PUB NO 20160229865A1
SERIAL NO

15022248

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BEIJING HANMI PHARMACEUTICAL CO LTDBEIJING 101312

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cha, Mi Young Beijing, CN 18 106
Kim, Maengsup Beijing, CN 11 52
Li, Gong Beijing, CN 15 52
Li, Zhanmei Beijing, CN 2 23
Liu, Jinming Beijing, CN 42 58
Qiu, Hongjuan Beijing, CN 2 23

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00